
Sign up to save your podcasts
Or


Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.
By Venrock, a venture capital firm4.8
6262 ratings
Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.

1,285 Listeners

2,706 Listeners

2,462 Listeners

1,096 Listeners

339 Listeners

322 Listeners

389 Listeners

5,562 Listeners

10,038 Listeners

34 Listeners

527 Listeners

21 Listeners

293 Listeners

473 Listeners

1,425 Listeners